Corporate Press Release

Tranzyme Pharma and Norgine Complete Enrolment in ULISES 008, the Second of Two Phase 3 Pivotal Trials of TZP-101

Companies on Track to Report Top-line Results in the First Half of 2012

RESEARCH TRIANGLE PARK, NC (February 29 2011) – Tranzyme Pharma (NASDAQ: TZYM) and Norgine B.V. today announced completion of patient enrolment in ULISES 008, the second of two Phase 3 pivotal trials of TZP-101 for the acceleration of gastrointestinal (GI) recovery in patients undergoing abdominal surgery. Enrolment in ULISES 007, the first Phase 3 pivotal trial, was completed in December 2011. There are an estimated 1 million patients in the U.S. at high risk each year for delayed GI recovery after surgery, including approximately 340,000 bowel resection surgeries[1].

"We are very pleased with the timely completion of enrolment in our second Phase 3 trial and expect to release top-line results of both trials in the first half of 2012. Further, we are focusing our efforts on preparing the TZP-101 NDA which we plan to submit to the U.S. FDA by year-end," said Franck S. Rousseau, M.D., Chief Medical Officer of Tranzyme Pharma.

The TZP-101 Phase 3 program includes two randomized, double-blind, placebo-controlled studies (ULISES 007 and 008). Approximately 330 bowel surgery patients have been enrolled at sites across the U.S. and Europe in each of these Phase 3 trials. The objective is to evaluate the efficacy and safety of daily 160 and 480µg/kg doses versus a placebo arm, with the primary endpoint being time to recovery of GI function defined as the time to the later of first bowel movement and tolerance of solid food.

ENDS

About TZP-101
TZP-101 is an intravenous ghrelin agonist discovered by Tranzyme using its proprietary drug discovery technology. TZP-101 is being developed in partnership with Norgine B.V., a specialty pharmaceutical company based in the Netherlands. Norgine holds the commercial rights for TZP-101 in Europe, Australia, New Zealand, Middle East, and North and South Africa.

References
1. http://hcupnet.ahrq.gov/

About Tranzyme Pharma
Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 20 percent of adults worldwide are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing an intravenous drug, TZP-101, for patients in acute (hospital-based) settings, as well as an oral drug, TZP-102, for chronic conditions. Top-line data from the recently completed Phase 3 trials of TZP-101 are expected in the first half of 2012, and enrolment in a Phase 2b trial of TZP-102 is ongoing. Together these product candidates target a significant underserved market. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

About Norgine
Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2011, Norgine's net product sales were €250 million. The Company employs over 1,200 people. Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a bowel cleansing preparation, KLEAN-PREP® for large bowel preparation prior to colonoscopy or surgery, XIFAXAN® for the treatment of traveller's diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer. Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France. For more information: www.norgine.com

Forward-Looking Statements
Statements in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements, including without limitation, those statements relating to the expected release date for clinical trial data and submission of the NDA for *TZP-101*, to be covered by the safe harbour provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbour provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks related to enrolment and successful completion of our trials, risk of unforeseen side effects, risks related to our collaborations and risks related to regulatory approval of new drug candidates. Further information on these and other factors that could affect the company's financial results is contained in our public filings with the Securities and Exchange Commission (SEC) from time to

time, including our Form 10-Q which was filed with the SEC on November 10, 2011, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Tranzyme Contacts
Corporate Inquiries:
Susan Sharpe
Director, Corporate Communications
(919) 328-1109
ssharpe@tranzyme.com

Investor Inquiries:
David Carey
Lazar Partners, Ltd.
(212) 867-1768
dcarey@lazarpartners.com

Norgine Contact
Julie Hornby Winfield
Global Corporate Communications Manager
+44 (0) 1895 826600
jhornbywinfield@norgine.com